Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Other Investing Activities

Investing cash flows not reported separately.

Abeona Therapeutics Inc.NASDAQ: ABEO

Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026

Other investing activities outflow grows to $0

Q1 FY2026 other investing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other investing activities was $152.37M. Over 3 fiscal years it compounded at +344.6% a year.

Context

  • Other investing activities amounted to 2618.0% of revenue in FY2025.
  • Other investing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other investing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $38.09M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$152.37M+846377.8% YoY
LTMMar 2026
$152.37M+846377.8% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+846377.8%——
3-year CAGR+344.6%——
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2025
152.37M USD
Year-over-year change
+846377.8%

Other Investing Activities vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 other investing activities of $152.37M is the largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +846377.8% is the highest of 3, against a peer median of -100.0%.
  • Other investing activities amounts to 1047.9% of revenue for ABEO, versus a peer median of 0.0%.
ABEO Competitors Peer median
Other Investing Activities for ABEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABEOAbeona Therapeutics Inc.LTM Mar 2026$152.37M +846377.8%+344.6%1047.9%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$1.21M ——1.7%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$225K ——0.5%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$0 ——0.0%
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 -100.0%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 ———
HUMAHumacyte, Inc.LTM Mar 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 ——0.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding ABEO) $0-100.0%—0.0%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
Deferred Income Tax00000
Stock-Based Compensation8.92M3.05M4.77M6.63M10.78M
Change in Working Capital(18.26M)(5.89M)(1.79M)(4.38M)(5.39M)
Accounts Receivables(3M)2.81M(2.04M)792K(5.06M)
Inventory0000(5.49M)
Accounts Payables(15.59M)(9.11M)2.04M(3.49M)6.54M
Other Working Capital324K404K(3.83M)(1.68M)(1.37M)
Other Non-Cash Items24.15M(5.52M)11M2.57M(156.46M)
Operating Cash Flow(65.67M)(43.48M)(37.01M)(56.02M)(76.33M)
Capital Expenditures(4.15M)(130K)(331K)(2.45M)(7.98M)
Acquisitions (Net)00000
Purchases of Investments(20.16M)(78.21M)(51.64M)(157.01M)(206.63M)
Sales of Investments90.38M52.64M51.97M120.2M167.27M
Other Investing Activities01.73M204K18K152.37M
Investing Cash Flow66.06M(23.96M)208K(39.24M)105.03M
Debt Repayment00020M0
Common Stock Issued24.03M46.96M37.39M85.63M26.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities831K(5K)(332K)(1.49M)(37K)
Financing Cash Flow24.86M43.17M37.06M104.14M26.04M
Effect of Forex Changes00000
Net Change in Cash25.26M(24.27M)256K8.88M54.74M
Free Cash Flow(69.82M)(43.61M)(37.34M)(58.46M)(84.3M)

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.